论文信息 - OA05.05 Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo + Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC) - 字舞流文

OA05.05 Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo + Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC)

K. Nackaerts | T. Owonikoko | D. Spigel | G. Ostoros | C. Baik | T. Csoszi | E. Sheldon-Waniga | D. Huebner | C. D. Ullmann | E. Leonard | E. Zagadailov | T. Csőszi | Claudio Dansky Ullmann | E Jane Leonard